Project CBD
MARCH 21, 2023
Auditory & Other Symptoms The survey, whose findings were published in February 2023 in the Journal of Otolaryngology – Head & Neck Surgery 1 evaluated cannabis perceptions and consumption among 45 adult tinnitus patients randomly selected and recruited from an outpatient ear, nose, and throat clinic in Ontario, Canada.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. On March 5, 2019, the U.S. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 30, 2019
This report contains a detailed summary of 2019’s federal and state legislative victories.” 2019 has been an unprecedented year for the passage of state-level marijuana law reforms. “Never before in American history has marijuana policy advanced in Congress as far or as fast in one year as 2019.
SpeedWeed
MAY 22, 2021
The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .
Cannabis Law Report
MAY 12, 2022
Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora expects LPH-5 to be IND ready in Q4 2022 and plans to begin first-in-human trials in 2023.
Project CBD
MAY 3, 2023
Dr. Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children.
Project CBD
OCTOBER 26, 2023
Goldstrich, MD, with Angela Bacca (Flower Valley Press, 2023). They conducted a double-blind, placebo-controlled phase 2 clinical trial using Sativex® in conjunction with temozolomide to treat recurrent glioblastoma multiforme (GBM). GW Pharmaceuticals’ research on glioblastoma multiforme (GBM) is important and promising.
Expert insights. Personalized for you.
144 
Let's personalize your content